Clinical Management of HCM: Medical, Invasive and Advanced Therapies
-
- Putting a clinical spotlight on HCM case studies
- Clinical Management of Hypertrophic Cardiomyopathy
- Improving Clinical Recognition of HCM
- Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
- Imaging for the Diagnosis and Management of HCM
- Clinical Implications of Genetic Testing in HCM
- HCM: An Introduction and Overview
-
- Putting a clinical spotlight on HCM case studies
- Clinical Management of Hypertrophic Cardiomyopathy
- Improving Clinical Recognition of HCM
- Sudden Cardiac Death Prevention in HCM: Where Do We Stand in 2021?
- Imaging for the Diagnosis and Management of HCM
- Clinical Implications of Genetic Testing in HCM
- HCM: An Introduction and Overview
Clinical Management of HCM: Medical, Invasive, and Advanced Therapies
Surgical and interventional options such as surgical myectomy or alcohol septal ablation may help those with obstructive HCM to reduce or remove the obstruction. A similar option is unavailable to those with non-obstructive HCM. Heart transplants are considered as a last resort for HCM patients who progress to end stages of the disease. Learn the latest in the clinical management of HCM in this free webinar.
Presenters: Anjali Tiku Owens, MD; Richard Bach, MD, FAHA, FACC, FSCAI
Moderator: James E. Udelson, MD, FAHA
Bristol Myers Squibb is a national sponsor of the American Heart Association’s hypertrophic cardiomyopathy initiative.
Anjali Tiku Owens, MD
Assistant Professor of Medicine
University of Pennsylvania
Professor of Medicine, Medical Director - Cardiac ICU
Washington university School of Medicine
Dr. James E. Udelson, MD, FAHA
Chief, Division of Cardiology,
Tufts Medical Center